04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
19:05 , Jul 20, 2017 |  BC Innovations  |  Translation in Brief

Lethal logic

Following the success of the PARP inhibitors in the clinic, researchers are now rushing to find more synthetic lethal interactions that can be exploited for therapeutic or diagnostic uses. A Stanford University team has risen...
21:19 , Nov 10, 2016 |  BC Innovations  |  Translation in Brief

Cutting the cancer fat

Nimbus Therapeutics LLC has shown one of its computationally designed acetyl-Coenzyme A carboxylase (ACC; ACAC) inhibitors, dubbed ND-646 , can block the fatty acid synthesis that fuels growth of lung tumors, and has developed a...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

Gilead preclinical data

In a mouse xenograft model of NSCLC, twice-daily 50 and 100 mg/kg oral ND-646 for 6 weeks significantly reduced total lung tumor burden by 80% and 82%, respectively, vs. vehicle-treated controls (p<0.01 for both). Data...
08:00 , Feb 5, 2015 |  BC Innovations  |  Product R&D

Addex's allosterics

Allosteric modulators are slowly filling the clinical pipeline, but finding the right assays to discover and characterize them properly still confounds companies in the space. Addex Therapeutics Ltd. is going back to basics and forging...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Clinical News

Nimbus Discovery preclinical data

In a rat model of diet-induced obesity, once-daily ND-630 reduced weight gain without affecting food intake, improved insulin sensitivity, dose-dependently reduced whole body fat markers, and reduced triglycerides, fatty acids and cholesterol to chow-fed control...
08:00 , Feb 4, 2013 |  BC Week In Review  |  Clinical News

Nimbus Discovery preclinical data

Nimbus said ND-630 inhibited hepatic fatty acid synthesis with an ED50 of 0.14 mg/kg and stimulated whole body fatty acid oxidation at a minimum effective dose of 3 mg/kg in rats. Data were presented at...
07:00 , Aug 28, 2008 |  BC Innovations  |  Targets & Mechanisms

Curbing Mitochondrial Appetite

Several companies have tried and failed to develop obesity drugs that agonize mitochondrial uncoupling proteins, which let adipose cells generate heat by burning excess fat. A new study now suggests that one member of this...